SYTL2: A Potential Drug Target and Biomarker (G54843)

Target Name: SYTL2

NCBI ID: G54843

SYTL2

SYTL2: A Potential Drug Target and Biomarker

Synovial cells, derived from the synovial membrane surrounding joints, are a crucial cell type that play a vital role in maintaining joint health and function. They produce and secrete various cytokines and growth factors, which contribute to the inflammatory response and tissue repair following injury or inflammation. The protein Sylvester Y (SYTL2) is one of these cytokines that is expressed in synovial cells and has been implicated in the pathogenesis of various inflammatory and autoimmune diseases.

SYTL2 is a member of the Y-type cytokine receptor family, which includes several structurally similar proteins, including SYTL3, GIT2, and FASL1. These proteins are involved in the regulation of cellular processes such as cell adhesion, migration, and survival. They also play important roles in the development and maintenance of tissues and organs, including the immune system and the nervous system.

SYTL2 is expressed in various tissues, including synovial tissue, bone marrow, and the skin. It is a potent regulator of inflammation and has been shown to play a crucial role in the development of inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and ankylosing spondylitis (AS).

SYTL2 has been shown to promote the recruitment and activation of immune cells, including T cells, macrophages, and B cells, in response to an inflammatory mediator. It also contributes to the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, which are involved in the regulation of immune cell function and the initiation of an inflammatory response.

In addition to its role in inflammation, SYTL2 has also been shown to be involved in the regulation of cellular processes that are important for tissue homeostasis, including cell survival and the regulation of cell-cell interactions. It has been shown to promote the formation of tight junctions, which are important for the regulation of ion and solute transport in tissues, and to play a role in the regulation of cell-cell adhesion.

SYTL2 has also been implicated in the development and progression of various cancers, including breast, ovarian, and prostate cancer. It has been shown to promote the growth and survival of cancer cells and to contribute to their invasiveness and metastasis.

Given the multifaceted role of SYTL2 in the regulation of cellular processes, it is a promising target for drug development. Several studies have identified potential small molecules that can inhibit the activity of SYTL2 and have shown that these compounds have therapeutic potential in various inflammatory and cancer-related diseases.

One of the most promising compounds that has been shown to inhibit the activity of SYTL2 is a compound called S42285, which is a potent inhibitor of SYTL2. S42285 has been shown to inhibit the activity of SYTL2 in a variety of cellular assays, including the inhibition of cell adhesion, migration, and the production of pro-inflammatory cytokines.

Another compound that has shown promise in the treatment of inflammatory and cancer-related diseases is a compound called PW-106260, which is a small molecule inhibitor of SYTL2. PW-106260 has been shown to be effective in treating a variety of inflammatory and cancer-related diseases, including RA, PA, and AS, as well as in treating various cancers.

While the role of SYTL2 in the development and progression of inflammatory and cancer-related diseases is still being fully understood, it is clear that it is an important target for further research and the development of new treatments. Further studies are needed to

Protein Name: Synaptotagmin Like 2

Functions: Isoform 1 acts as a RAB27A effector protein and plays a role in cytotoxic granule exocytosis in lymphocytes. It is required for cytotoxic granule docking at the immunologic synapse. Isoform 4 binds phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) and promotes the recruitment of glucagon-containing granules to the cell membrane in pancreatic alpha cells. Binding to PS is inhibited by Ca(2+) while binding to PIP2 is Ca(2+) insensitive

The "SYTL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYTL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets